Get the Stockscreener App
23.41
0.85%
-0.23
Beam Therapeutics Inc Stock (BEAM) Latest News
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com Australia
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
Beam Therapeutics stock target holds at $37 on positive trial data - Investing.com Canada
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - Dealbreaker
Beam Therapeutics stock target holds at $37 on positive trial data By Investing.com - Investing.com South Africa
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty - TipRanks
Beam Therapeutics (NASDAQ:BEAM) Receives “Buy” Rating from HC Wainwright - Defense World
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Wainwright holds Beam stock Buy rating, $80 target after trial data - Investing.com
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics - Genetic Engineering & Biotechnology News
Proficio Capital Partners LLC Makes New $406,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics, Lennar, Redfin - TradingView
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Scotiabank to “Sector Outperform” Rating - Defense World
Beam Therapeutics’ (BEAM) Outperform Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Jones Trading to Buy Rating - Defense World
Scotiabank Upgrades Beam Therapeutics (BEAM) - Nasdaq
Beam Gets Important Proof Of Concept For AATD Therapy - Citeline News & Insights
Beam Therapeutics: Single-Base Editing Seems To Work - Seeking Alpha
Beam drops 9% on phase 1/2 data for genetic lung disease candidate - Seeking Alpha
JonesResearch upgrades Beam Therapeutics to Buy on de-risking data - TipRanks
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright - TipRanks
Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target - TipRanks
Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target - Marketscreener.com
Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst - TipRanks
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - Insider Monkey
Beam launches $500m financing on base-editing trial data - pharmaphorum
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga
Beam Therapeutics Prices $500 Million Share, Warrant Offering -March 10, 2025 at 08:15 am EDT - Marketscreener.com
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition - STAT
Beam Therapeutics rises on early-stage trial results for gene editing therapy - TradingView
Beam Therapeutics Announces Positive Initial Data For BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating - TipRanks
Beam Therapeutics stock soars on positive BEAM-302 trial data - Investing.com
Beam Therapeutics stock soars on positive BEAM-302 trial data By Investing.com - Investing.com Canada
Beam Therapeutics Shares Surge on Promising Trial Data - TipRanks
Beam Therapeutics Reports Positive Phase 1/2 Trial Data - TipRanks
Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD - Nasdaq
Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels -March 10, 2025 at 06:11 am EDT - Marketscreener.com
Beam Therapeutics Reports Promising Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Clinical Trial - Nasdaq
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - The Manila Times
Beam Therapeutics announces ‘positive’ data from study of BEAM-302 - TipRanks
Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire
Beam Therapeutics Secures $500M Financing for Clinical Programs - StockTitan
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation | Dow Theory Letters - Financial Content
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates - MSN
0.37%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):